CXCL8 and cancer: Serum IL-8 has been recently analyzed in several different ICI trials for different cancers, including mRCC, and results suggest that IL-8 might represent a negative prognostic biomarker for solid tumors, but that it might also represent a biomarker of resistance to ICI treatment, hence aiding in predicting response to therapy (25, 26).